Compositions for delivering peptide yy and pyy agonists

Abstract

The present invention provides a composition (e.g., a pharmaceutical composition) comprising at least one delivery agent compound and at least one of peptide YY (PYY) and a PYY agonist. Preferably, the composition includes a therapeutically effective amount of peptide YY or the PYY agonist and the delivery agent compound. The composition of the present invention facilitates the delivery of PYY, a PYY agonist, or a mixture thereof and increases its bioavailability compared to administration without the delivery agent compound. PPY and PYY agonists possess activity as agents to reduce nutrient availability, including reduction of food intake.

1 . A dosage unit form for oral administration comprising (a) at least one peptide YY, a peptide YY agonist, or a mixture thereof, and (b) a delivery agent of the formula 
       
         
           
           
               
               
           
         
       
       or a salt thereof, wherein:
 Ar is phenyl or naphthyl; 
 Ar is optionally substituted with one or more of —OH, halogen, C 1 -C 4  alkyl, C 1 -C 4  alkenyl, C 1 -C 4  alkoxy or C 1 -C 4  haloalkoxy; 
 R 7  is selected from C 4 -C 20  alkyl, C 4 -C 20  alkenyl, phenyl, naphthyl, (C 1 -C 10  alkyl)phenyl, (C 1 -C 10  alkenyl)phenyl, (C 1 -C 10  alkyl) naphthyl, (C 1 -C 10 ) alkenyl) naphthyl, phenyl(C 1 -C 10  alkyl), phenyl(C 1 -C 10  alkenyl), naphthyl(C 1 -C 10  alkyl), or naphthyl(C 1 -C 10  alkenyl); 
 R 8  is selected from hydrogen, C 1  to C 4  alkyl, C 2  to C 4  alkenyl, C 1  to C 4  alkoxy, and C 1 -C 4  haloalkoxy; 
 R 7  is optionally substituted with C 1  to C 4  alkyl, C 2  to C 4  alkenyl, C 1  to C 4  alkoxy C 1 -C 4  haloalkoxy, —OH, —SH, and —CO 2 R 9 , or any combination thereof; 
 R 9  is hydrogen, C 1  to C 4  alkyl, or C 2  to C 4  alkenyl; and 
 R 7  is optionally interrupted by oxygen, nitrogen, sulfur or any combination thereof. 
 
     
     
         2 . A dosage unit form for oral administration comprising (a) at least one peptide YY, a peptide YY agonist, or a mixture thereof, and (b) a delivery agent of the formula 
       
         
           
           
               
               
           
         
       
       or a salt thereof, wherein
 R 1 , R 2 , R 3 , and R 4  are independently H, —OH, halogen, C 1 -C 4  alkyl, C 2 -C 4  alkenyl, C 1 -C 4  alkoxy, —C(O)R 8 , —NO 2 , —NR 9 R 10 , or —N + R 9 R 10 R 11 (R 12 )—; 
 R 5  is H, —OH, —NO 2 , halogen, —CF 3 , —NR 14 R 15 , —N + R 14 R 15 R 16  (R 13 ) − , amide, C 1 -C 12  alkoxy, C 1 -C 12  alkyl, C 2 -C 12  alkenyl, carbamate, carbonate, urea, or —C(O)R 18 ; 
 R 5  is optionally substituted with halogen, —OH, —SH, or —COOH; 
 R 5  is optionally interrupted by O, N, S, or —C(O)—; 
 R 6  is a C 1 -C 12  alkylene, C 2 -C 12  alkenylene, or arylene; 
 R 6  is optionally substituted with a C 1 -C 4  alkyl, C 2 -C 4  alkenyl, C 1 -C 4  alkoxy, —OH, —SH, halogen, —NH 2 , or —CO 2 R 8 ; 
 R 6  is optionally interrupted by O or N; 
 R 7  is a bond or arylene; 
 R 7  is optionally substituted with —OH, halogen, —C(O)CH 3 , —NR 10 R 11 , or —N + R 10 R 11 R 12  (R 13 ) − ; 
 R 8  is H, C 1 -C 4  alkyl, C 2 -C 4  alkenyl, or —NH 2 ; 
 R 9 , R 10 , R 11 , and R 12  independently H or C 1 -C 10  alkyl; 
 R 13  is a halide, hydroxide, sulfate, tetrafluoroborate, or phosphate; and 
 R 14 , R 15  and R 16  are independently H, C 1 -C 10  alkyl, C 1 -C 10  alkyl substituted with —COOH, C 2 -C 12  alkenyl, C 2 -C 12  alkenyl substituted with —COOH, —C(O)R 17 ; 
 R 17  is —OH, C 1 -C 10  alkyl, or C 2 -C 12  alkenyl; and 
 R 18  is H, C 1 -C 6  alkyl, —OH, —NR 14 R 15 , or N + R 14 R 15 R 16 (R 13 ). 
 
     
     
         3 . A dosage unit form for oral administration comprising (a) at least one peptide YY, a peptide YY agonist, or a mixture thereof, and (b) a delivery agent of the formula 
       
         
           
           
               
               
           
         
       
       or a salt thereof, wherein
 R 1 , R 2 , R 3 , R 4  and R 5  are independently H, —CN, —OH, —OCH 3 , or halogen, at least one of R 1 , R 2 , R 3 , R 4  and R 5  being —CN; and 
 R 6  is C 1 -C 12  linear or branched alkylene, alkenylene, arylene, alkyl(arylene) or aryl(alkylene). 
 
     
     
         4 . The dosage unit form of  claim 1 , wherein the delivery agent is selected from the group consisting of the monosodium salt of N-(8-[2-hydroxybenzoyl]-amino)caprylic acid, the monosodium salt of N-(10-[2-hydroxybenzoyl]-amino)decanoic acid, the monosodium salt of 8-(2-hydroxy-4-methoxybenzoylamino)octanoic acid, the monosodium salt of 8-(2,6-dihydroxybenzoylamino)octanoic acid, the monosodium salt of 8-(2-hydroxy-5-bromobenzoylamino)actanoic acid, the monosodium salt 8-(2-hydroxy-5-chlorobenzoylamino)octanoic acid, the monosodium salt of 8-(2-hydroxy-5-iodobenzoylamino)octanoic acid, the monosodium salt of 8-(2-hydroxy-5-methylbenzoylamino)octanoic acid, the monosodium salt of 8-(2-hydroxy-5-fluorobenzoylamino)octanoic acid, the monosodium salt of 8-(2-hydroxy-5-methoxybenzoylamino)octanoic acid, the monosodium salt of 8-(3-hydroxyphenoxy)octanoic acid, the monosodium salt of 8-(4-hydroxyphenoxy)octanoic acid, the monosodium salt of 6-(2-cyanophenoxy)hexanoic acid, the monosodium salt of 8-(2-hydroxyphenoxy)octyl-diethanolamine, disodium salt of N-(10-[2-hydroxybenzoyl]-amino)decanoic acid, the disodium salt of 8-(4-hydroxyphenoxy)octanoate, the monosodium salt of 8-(4-hydroxyphenoxy)octanoate, the disodium salt of 8-(2-hydroxy-4-methoxybenzoylamino)octanoic acid, and the disodium salt of 8-(2-hydroxy-5-methoxybenzoylamino)octanoic acid. 
     
     
         5 . The dosage unit form of  claim 1  wherein the delivery agent is N-(8-[2-hydroxybenzoyl]-amino)caprylic acid or a pharmaceutically acceptable salt thereof. 
     
     
         6 . The dosage unit form of  claim 1  wherein the delivery agent is N-(10-[2-hydroxybenzoyl]-amino)decanoic acid or a pharmaceutically acceptable salt thereof. 
     
     
         7 . The dosage unit form of  claim 1 , wherein the peptide YY agonist is selected from the functional domain of PYY, active fragments of PYY, derivatives of PYY, fragments of PYY, or analogs of PYY. 
     
     
         8 . The dosage unit form of  claim 1 , wherein the peptide YY agonist is PYY[3-36]. 
     
     
         9 . A dosage unit form comprising:
 (A) the dosage unit form of  claim 1 ; and   (B) (a) an excipient,
 (b) a diluent, 
 (c) a disintegrant, 
 (d) a lubricant, 
 (e) a plasticizer, 
 (f) a colorant, 
 (g) a dosing vehicle, or 
 (h) any combination thereof. 
   
     
     
         10 . The dosage unit form of  claim 9 , wherein the dosage unit form is in the form of a tablet, a capsule, a particle, a powder, a sachet, or a liquid. 
     
     
         11 . The dosage unit form of  claim 9 , wherein the dosing vehicle is a liquid selected from the group consisting of water, aqueous propylene glycol, phosphate buffer, 1,2-propane diol, ethanol, and any combination thereof. 
     
     
         12 . A method for administering an effective amount of peptide YY or a peptide YY agonist to a patient in need of thereof, comprising the step of orally administering the dosage unit form of  claim 1 . 
     
     
         13 . The method of  claim 12  wherein the peptide YY agonist is PYY[3-36] and the delivery agent is N-(8-[2-hydroxybenzoyl]-amino)caprylic acid or N-(10-[2-hydroxybenzoyl]-amino)decanoic acid or a pharmaceutically acceptable salt thereof. 
     
     
         14 . A method of treating obesity in a patient in need thereof, comprising the step of orally administering to the patient an effective amount of the dosage unit form of  claim 1 . 
     
     
         15 . A method of treating a condition or disorder that may be alleviated by reducing nutrient availability in a patient in need thereof, comprising the step of orally administering to an animal an effective amount of the dosage unit form of  claim 1 . 
     
     
         16 . The method of  claim 15  wherein the condition or disorder is selected from the group consisting of hypertension, dyslipidemia, cardiovascular risk, an eating disorder, insulin-resistance, obesity and diabetes mellitus, or any combination thereof. 
     
     
         17 . The method of  claim 15  wherein the condition or disorder is selected from the group consisting of cancer, cachexia and malnutrition, or any combination thereof. 
     
     
         18 . A method of reducing nutrient uptake in a patient in need thereof, comprising the step of orally administering an effective amount of the dosage unit form of  claim 1 . 
     
     
         19 . A method of improving the lipid profile in a patient in need thereof, comprising the step of orally administering an effective amount of the dosage unit form of  claim 1 . 
     
     
         20 . A method of improving the bioavailability of a peptide YY, a peptide YY agonist, or both, in an animal, the method comprising the step of orally administering the dosage unit form of  claim 1 . 
     
     
         21 . (canceled)